328

MEIRAGTX HLDGSDL-0000388

Healthcare · EUR · F

328

Price

€8.006

-1.37%

Cap

€909.07M

Earnings

30d Trend

-10.3%

328
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

64% annualised over 90 days

BRAIN47 SIGNAL

0
MODERATE
Risk Level73
Quality35
Momentum78
Technical58
Fundamentals50

Raw weighted: 52×Macro 0.99 (1%)=51

RISK

73/100
90d Volatility
63.9%High
ATR %
5.0%High daily moves
Max Drawdown (1Y)
-24.5%Normal

QUALITY

35/100
Piotroski F-Score
2/9Weak
Accruals
-27.8%Cash earnings

MOMENTUM

78/100
12-1M Momentum
+74.8%Strong uptrend
6-1M Momentum
+8.8%Positive
1M Return
+11.7%Strong recent gains

TECHNICAL

58/100
RSI (14)
57.3Neutral
Price vs SMA200
+20.9%Bullish trend
MACD
0.00Bearish momentum
Bollinger Band
84%Near upper band
SMA Cross
Death CrossDeath Cross
Trend Quality (KER)
0.258Noisy/choppy

FUNDAMENTALS

50/100

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 80%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months54
3-12 months82
1-5+ years47

6-9 month momentum thesis — strong trend with confirmation

BRAIN47'S ASSESSMENT

I rate MEIRAGTX HLDGSDL-0000388 at 51/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 78/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.

PAST PERFORMANCE

1 MONTH

+11.7%

3 MONTHS

+32.3%

12 MONTHS

+86.6%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

6-9 month momentum thesis — strong trend with confirmation. Momentum (78) and Technical (58) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 64%. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.

growthScore: 51/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.